TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Tarsus Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$69.50+1.43 (+2.10%)
Close on Oct 19, 2026
- Market cap
- $3.02B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Tarsus Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $173.91M | $145.39M | $151.67M | $118.70M | $102.66M | $78.34M | $66.41M | $48.12M | $40.81M | $24.72M | $13.08M | $1.65M | 100.0% | +69.4% |
| License fees and collaboration revenue | $0 | $16.67M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.89M | $0 | $218.00K | 0.0% | – |
| License And Collaboration, Other | – | – | – | – | – | – | – | $0 | $0 | $0 | $0 | $200.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Tarsus Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.